- Home
- PHLT vs IOVA Comparison
PHLT vs IOVA Comparison
Compare PHLT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHLT
- IOVA
- Stock Information
- Founded
- PHLT 1976
- IOVA 2007
- Country
- PHLT United States
- IOVA United States
- Employees
- PHLT N/A
- IOVA N/A
- Industry
- PHLT Other Consumer Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHLT Consumer Discretionary
- IOVA Health Care
- Exchange
- PHLT Nasdaq
- IOVA Nasdaq
- Market Cap
- PHLT 601.2M
- IOVA 975.1M
- IPO Year
- PHLT N/A
- IOVA N/A
- Fundamental
- Price
- PHLT $7.68
- IOVA $2.22
- Analyst Decision
- PHLT Buy
- IOVA Buy
- Analyst Count
- PHLT 2
- IOVA 11
- Target Price
- PHLT $7.88
- IOVA $11.90
- AVG Volume (30 Days)
- PHLT 1.2M
- IOVA 9.5M
- Earning Date
- PHLT 11-05-2025
- IOVA 11-06-2025
- Dividend Yield
- PHLT N/A
- IOVA N/A
- EPS Growth
- PHLT N/A
- IOVA N/A
- EPS
- PHLT N/A
- IOVA N/A
- Revenue
- PHLT $137,357,000.00
- IOVA $241,525,000.00
- Revenue This Year
- PHLT $12.38
- IOVA $67.40
- Revenue Next Year
- PHLT $10.09
- IOVA $56.32
- P/E Ratio
- PHLT N/A
- IOVA N/A
- Revenue Growth
- PHLT 15.21
- IOVA 636.99
- 52 Week Low
- PHLT $2.17
- IOVA $1.64
- 52 Week High
- PHLT $7.74
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- PHLT 80.74
- IOVA 43.75
- Support Level
- PHLT $7.56
- IOVA $2.27
- Resistance Level
- PHLT $7.67
- IOVA $2.38
- Average True Range (ATR)
- PHLT 0.03
- IOVA 0.14
- MACD
- PHLT -0.10
- IOVA -0.01
- Stochastic Oscillator
- PHLT 81.82
- IOVA 28.21
About PHLT Performant Healthcare Inc. Common Stock
Performant Healthcare Inc provides solutions to payers in the healthcare industry to identify, prevent, and recover waste and improper payments by leveraging technology, analytics, and proprietary data assets.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.